Clarius Group LLC purchased a brand new place in shares of Quest Diagnostics Integrated (NYSE:DGX – Free Report) within the third quarter, based on the corporate in its most up-to-date 13F submitting with the Securities and Trade Fee (SEC). The institutional investor purchased 1,353 shares of the medical analysis firm’s inventory, valued at roughly $210,000.
Numerous different hedge funds and different institutional traders have additionally lately modified their holdings of DGX. Rothschild Funding LLC purchased a brand new place in shares of Quest Diagnostics throughout the second quarter value $26,000. Spartan Planning & Wealth Administration purchased a brand new place in Quest Diagnostics throughout the fourth quarter valued at $31,000. Innealta Capital LLC purchased a brand new place in Quest Diagnostics throughout the second quarter valued at $31,000. Larson Monetary Group LLC lifted its place in Quest Diagnostics by 77.5% throughout the second quarter. Larson Monetary Group LLC now owns 229 shares of the medical analysis firm’s inventory valued at $31,000 after buying a further 100 shares over the last quarter. Lastly, Riverview Belief Co purchased a brand new place in Quest Diagnostics throughout the first quarter valued at $33,000. Institutional traders personal 88.06% of the corporate’s inventory.
Insider Exercise
In different information, SVP Mark E. Delaney bought 420 shares of the agency’s inventory in a transaction dated Wednesday, July twenty fourth. The shares had been bought at a mean worth of $143.08, for a complete worth of $60,093.60. Following the sale, the senior vice chairman now straight owns 5,019 shares within the firm, valued at roughly $718,118.52. This commerce represents a 0.00 % lower of their place. The transaction was disclosed in a submitting with the Securities & Trade Fee, which is accessible via this hyperlink. In different Quest Diagnostics information, SVP Karthik Kuppusamy bought 1,990 shares of the agency’s inventory in a transaction that occurred on Wednesday, August twenty eighth. The shares had been bought at a mean worth of $153.26, for a complete transaction of $304,987.40. Following the completion of the transaction, the senior vice chairman now straight owns 11,459 shares of the corporate’s inventory, valued at roughly $1,756,206.34. This commerce represents a 0.00 % lower of their place. The transaction was disclosed in a submitting with the SEC, which might be accessed via this hyperlink. Additionally, SVP Mark E. Delaney bought 420 shares of the agency’s inventory in a transaction that occurred on Wednesday, July twenty fourth. The inventory was bought at a mean worth of $143.08, for a complete transaction of $60,093.60. Following the transaction, the senior vice chairman now straight owns 5,019 shares of the corporate’s inventory, valued at $718,118.52. This represents a 0.00 % lower of their possession of the inventory. The disclosure for this sale might be discovered right here. Firm insiders personal 0.79% of the corporate’s inventory.
Quest Diagnostics Buying and selling Up 0.6 %
DGX inventory opened at $148.67 on Friday. The corporate has a market capitalization of $16.55 billion, a PE ratio of 20.06, a P/E/G ratio of two.45 and a beta of 0.89. Quest Diagnostics Integrated has a 12 month low of $120.10 and a 12 month excessive of $159.36. The agency’s 50-day transferring common is $152.51 and its 200 day transferring common is $143.34. The corporate has a debt-to-equity ratio of 0.57, a present ratio of 1.00 and a fast ratio of 0.91.
Quest Diagnostics (NYSE:DGX – Get Free Report) final posted its earnings outcomes on Tuesday, July twenty third. The medical analysis firm reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.31 by $0.04. The enterprise had income of $2.40 billion for the quarter, in comparison with the consensus estimate of $2.39 billion. Quest Diagnostics had a internet margin of 8.99% and a return on fairness of 15.35%. The corporate’s income for the quarter was up 2.5% on a year-over-year foundation. Throughout the identical quarter final 12 months, the agency posted $2.30 EPS. On common, analysis analysts anticipate that Quest Diagnostics Integrated will submit 8.89 EPS for the present 12 months.
Quest Diagnostics Declares Dividend
The corporate additionally lately declared a quarterly dividend, which can be paid on Monday, October twenty first. Stockholders of document on Friday, October 4th can be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized foundation and a dividend yield of two.02%. The ex-dividend date of this dividend is Friday, October 4th. Quest Diagnostics’s dividend payout ratio is at present 40.49%.
Wall Road Analyst Weigh In
A number of analysis corporations have commented on DGX. Robert W. Baird elevated their worth goal on shares of Quest Diagnostics from $153.00 to $154.00 and gave the corporate a “impartial” score in a analysis report on Wednesday, July twenty fourth. Evercore ISI began protection on shares of Quest Diagnostics in a analysis report on Wednesday, August twenty eighth. They set an “in-line” score and a $165.00 worth goal for the corporate. Truist Monetary elevated their goal worth on shares of Quest Diagnostics from $158.00 to $165.00 and gave the corporate a “maintain” score in a analysis notice on Monday, October seventh. Piper Sandler elevated their goal worth on shares of Quest Diagnostics from $145.00 to $150.00 and gave the corporate a “impartial” score in a analysis notice on Monday, July twenty ninth. Lastly, Citigroup raised shares of Quest Diagnostics from a “impartial” score to a “purchase” score and elevated their goal worth for the corporate from $145.00 to $165.00 in a analysis notice on Wednesday, July tenth. Ten analysis analysts have rated the inventory with a maintain score and 4 have issued a purchase score to the inventory. In accordance with information from MarketBeat.com, Quest Diagnostics at present has a consensus score of “Maintain” and a mean worth goal of $154.92.
Get Our Newest Inventory Report on Quest Diagnostics
Quest Diagnostics Profile
Quest Diagnostics Integrated offers diagnostic testing and providers in the USA and internationally. The corporate develops and delivers diagnostic info providers, similar to routine, non-routine and superior medical testing, anatomic pathology testing, and different diagnostic info providers.
Featured Articles
Obtain Information & Rankings for Quest Diagnostics Day by day – Enter your electronic mail handle under to obtain a concise day by day abstract of the most recent information and analysts’ scores for Quest Diagnostics and associated corporations with MarketBeat.com’s FREE day by day electronic mail e-newsletter.
